Trial Profile
Post-operative adjuvant interferon-alfa-2B (intron-A) treatment after resection of thick primary melanoma and/or regional lymphnode metastases 'intermediate-high dose' vs intermediate-low dose' IFN-ALFA [interferon-alfa] vs observation: a 3-arm multicenter randomized phase III trial.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Oct 2005 New trial record.